Fusogenic Lipid Nanovesicles as Multifunctional Immunomodulatory Platforms for Precision Solid Tumor Therapy

Area of Science:

• Biomedical Engineering
• Immunology
• Nanotechnology

Background:

• Clinical efficacy of cancer immunotherapy is limited by poor tumor immunogenicity, inadequate immune activation, and immunosuppressive tumor microenvironment (TME).
• Lipid nanovesicles with membrane fusion capabilities (LNV-Fs) are emerging as a promising platform to overcome these limitations.

Purpose of the Study:

• To provide a comprehensive analysis of LNV-F systems for cancer immunotherapy.
• To explore structural classifications, membrane fusion mechanisms, and applications of LNV-Fs.
• To discuss future prospects, including artificial intelligence-assisted design, for LNV-Fs in precision immunotherapy.

Main Methods:

• Review of recent advancements in LNV-F systems for cancer immunotherapy.
• Analysis of LNV-F structural classifications and membrane fusion mechanisms.
• Exploration of LNV-F applications in enhancing anti-tumor immunity, cell therapies, and TME reprogramming.

Main Results:

• LNV-Fs mimic natural membrane fusion to present immunogenic components on tumor cells, activating anti-tumor immune surveillance.
• LNV-Fs can functionalize effector cells for enhanced cell therapies and act as vaccines for robust anti-tumor immunity and memory.
• LNV-Fs demonstrate significant potential in reprogramming the immunosuppressive TME.

Conclusions:

• LNV-F systems represent a versatile and universal platform for modulating the immune response against solid tumors.
• Further research and development, including AI-assisted design, hold significant promise for advancing precision cancer immunotherapy using LNV-Fs.